These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11980623)

  • 1. Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men.
    Rolf C; Kemper S; Lemmnitz G; Eickenberg U; Nieschlag E
    Eur J Endocrinol; 2002 May; 146(5):673-9. PubMed ID: 11980623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation.
    Rolf C; Knie U; Lemmnitz G; Nieschlag E
    Clin Endocrinol (Oxf); 2002 May; 56(5):637-41. PubMed ID: 12030915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
    Kamischke A; Venherm S; Plöger D; von Eckardstein S; Nieschlag E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):303-9. PubMed ID: 11232016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial.
    Zitzmann M; Rohayem J; Raidt J; Kliesch S; Kumar N; Sitruk-Ware R; Nieschlag E
    Andrology; 2017 May; 5(3):516-526. PubMed ID: 28189123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men.
    Qoubaitary A; Meriggiola C; Ng CM; Lumbreras L; Cerpolini S; Pelusi G; Christensen PD; Hull L; Swerdloff RS; Wang C
    J Androl; 2006; 27(6):853-67. PubMed ID: 16837736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
    Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
    Meikle AW; Matthias D; Hoffman AR
    BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men.
    Dobs AS; Matsumoto AM; Wang C; Kipnes MS
    Curr Med Res Opin; 2004 May; 20(5):729-38. PubMed ID: 15140340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men.
    Scott JD; Wolfe PR; Anderson P; Cohan GR; Scarsella A
    HIV Clin Trials; 2007; 8(6):412-20. PubMed ID: 18042506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101.
    Wittert GA; Harrison RW; Buckley MJ; Wlodarczyk J
    Andrology; 2016 Jan; 4(1):41-5. PubMed ID: 26754331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men.
    Mahabadi V; Amory JK; Swerdloff RS; Bremner WJ; Page ST; Sitruk-Ware R; Christensen PD; Kumar N; Tsong YY; Blithe D; Wang C
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2313-20. PubMed ID: 19366848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and bioavailability of a new testosterone gel formulation in comparison to Testogel® in healthy men.
    Olsson H; Sandström R; Neijber A; Carrara D; Grundemar L
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):358-64. PubMed ID: 27129008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.